Portal de Periódicos da CAPES

Revisão Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety

2017; Future Medicine; Volume: 6; Issue: 2 Linguagem: Inglês

10.2217/cer-2016-0045

2042-6313

Isabella Piassi Dias Godói, Lívia Lovato Pires de Lemos, Vânia Eloísa de Araújo, Braúlio Cesar Bonoto, Brian Godman, Augusto Afonso Guerra,

Viral Infections and Outbreaks Research

Introduction: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia ® ) was the first vaccine to gain regulatory approval to try and address this problem. Aim: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine. Method: Meta-analysis and systematic review. Results: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2–16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events. Conclusion: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.